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Evaluating Value-Based Frameworks Used for Relapsed and Refractory Multiple Myeloma 
Regimens: ASCO value framework, ICER Report and NCCN Evidence Blocks 
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Background 
• Approximately 11.5 % of the US total drug  costs are derived from oncology 
treatments, amounting nearly $38 billion in 2015. Experts suggest annual costs for 
oncology care will continue to rise between 7.5 to 10.5 % each year through 2020, 
accounting for over $140 billion in the U.S. alone. 1 
• With the continuous rise in costs for oncology drugs, the Institute for Clinical and 
Economic Review (ICER), the American Society of Clinical Oncology (ASCO) and the 
National Comprehensive Cancer Network (NCCN) have developed value-based 
frameworks (VBFs) to assist stakeholders in formulary and treatment decision-
making. 2 
• While emerging VBFs have the potential to significantly impact therapeutic options 
for patients, it is important to understand the differences associated with those 
VBFs within a therapeutic area.  
• Despite the proliferation of recent literature assessing , validity, reliability, and 
practicality of VBFs, few studies have critically evaluated all available models for 
oncology  regimens and their potential impact on real world decision making. 3,4  
There is no study to date that has compared the value of cancer regimens for a 
specific disease state across all oncology VBFs available in the US. 
Objective  
• To compare ASCO, ICER and NCCN VBFs across three therapeutic options for 
relapsed or refractory multiple myeloma (RRMM) 
Methods   
Overview of the study  
• A literature reviewed was performed and three VBFs were utilized to assess the 
value of oncology drugs in the US: the American Society of Clinical Oncology (ASCO) 
VBF, the National Comprehensive Cancer Network (NCCN) Evidence Blocks and the 
Institute for Clinical and Economic Review (ICER)  
• The four authors used each VBF to determine the RRMM treatment of greatest 
value by performing a test case analysis for each VBF 
 
The test case: multiple myeloma drugs 
Four inclusion criteria for the selection of oncology drugs 
    (1) Recently approved by the FDA  
    (2) Available results of a phase III clinical trial 
    (3) Same standard of care as the comparator in clinical  trials  
    (4) Availability of reports for NCCN and ICER , and the availability of  data to plug in 
the ASCO framework 
• Based on those inclusion criteria,  Carfilzomib (CFZ), Elotuzumab (ELO), Ixazomib 
(IX)  in combination with Lenalidomide + dexamthasone (LEN +DEX) were chosen 
 
Oncology value frameworks and usability in the test case 
 
The authors used the updated 2016  ASCO VBF to generate the 
value of CFZ, ELO and IX 
• Net health benefit (NHB): clinical benefit , toxicity and bonus 
points were calculated using phase III clinical trial of each 
regimen 
• Cost: wholesale acquisition cost (WAC) obtained from Medi-Span 
Price Rx and Redbook pricing references. Cost of each regimen 
was calculated using a standard weight-based dosing of 70kg, 
height of 170 cm 
Published 2016 Multiple Myeloma NCCN evidence blocks report 
• 5 blocks: efficacy, safety, quality, consistency, and affordability 
• Score ranging from 1 to 5: 1 as the least favorable and 5 as the 
most favorable 
Published ICER 2016 report of treatment options for RRMM 
• Comparative clinical effectiveness results  
• Cost-effectiveness analysis results (cost/ QALYS) for second and 
third line regimens 
• Budget Impact analysis results (cost) for second and third line 
regimens  
Results  
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Figure 2a. Net health benefit of each RRMM regimens  
Figure 2b. Cost associated with each RRMM regimen  
ICER Report 
Comparative clinical effectiveness: all regimens received an equal rating of B+  
 
Figure 1. NCCN Evidence Blocks report of each regimen   
Table 1. Cost effectiveness analysis  results (costs per QALYs)  
Discussion  
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• Previous research demonstrated that while these VBF capture important value to 
diverse audience, they lack consistency and are presented with analytic challenges 
related to their use.4 Furthermore, the use of ASCO VBF in clinical decision making 
requires further specificity.3 
Limitations 
• While there is a number of therapies available to treat RRMM, this study was able to 
capture and analyze only three FDA approved treatment 
• There were some discrepancies between authors about the  results of the ASCO VBFs  
• Challenges and limitations associated with these VBFs  should be further evaluated 
before implementation in practice 
• Even though all VBFs suggested CFZ as the best option, the usability of VBF in formulary 
decision-making process remains unclear  
Results  
NCCN Evidence Blocks 
E= Efficacy of regimen/agent; S= Safety of regimen/agent; Q= Quality of evidence;  
C= Consistency of evidence; A= Affordability of regimen/agent  
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CFZ + LEN + DEX $199,982  32%-64% 
ELO + LEN + DEX $427,607  75%-89% 
IX + LEN +DEX $433,794  80%-94% 
Drug  Third line  Discount from list price  
CFZ + LEN + DEX $238,560  48%-77% 
ELO + LEN + DEX $481,244  80%-93% 
IX + LEN +DEX $484,582  85%-97% 
Figure 3. Budget Impact Analysis Results (Average costs/year, millions) 
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Overall results 
• ICER, ASCO and NCCN VBFs suggest CFZ, in combination with LEN + DEX may be the 
most valued treatment out of the three regimens  
